Early-Phase Oral Antiviral Use and Post-COVID-19 Condition in Outpatients.

JAMA Netw Open · 2026 · PMC13179545 · PMID 42138923

Europe PMC DOI

hedged sentence

0.4700

closest p · 9.4× alpha

0.4700

boldest claim

The sentences

did not reach statistical significanceP = .47not close (p > 0.1)

For nirmatrelvir, point estimates favored nirmatrelvir use, but the association did not reach statistical significance (98 participants receiving nirmatrelvir; aRR, 0.88; 95% CI, 0.63–1.24; P = .47; aRD, −3.53 pp; 95% CI, −12.13 to 5.07 pp; P = .42) ( Figure 2 ; eTable 8 in Supplement 1 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.